Literature DB >> 15016014

Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam.

C-M Lokrantz1, B Eriksson, I Rosén, F Asztely.   

Abstract

We describe the clinical and neurophysiological findings in a case of hyperammonemic encephalopathy. A 72-year-old woman taking valproate (VPA), as monotherapy for her partial epilepsy developed urinary tract infection. She was treated with pivmecillinam 600 mg daily. The following days she deteriorated and became stuporous. At admission her serum ammonia level was increased (113 mmol/l) but the liver function appeared normal. EEG showed bilateral triphasic waves and continuous high-amplitude delta-theta wave. The patient recovered rapidly after discontinuation of VPA and i.v. treatment with cefuroxime for her urinary tract infection. VPA-induced hyperammonemic encephalopathy in adults is a rare phenomenon, especially when VPA is used as monotherapy. It has been suggested that the VPA-induced hyperammonemic encephalopathy is due to reduced serum carnitine concentration. Pivmecillinam, a widely used antibiotic for treatment of urinary tract infections, is also known to decrease the serum carnitine concentration. Our case shows that caution is required when treatment with VPA is combined with pivmecillinam due to the risk of developing hyperammonemic encephalopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016014     DOI: 10.1046/j.1600-0404.2003.00227.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  9 in total

Review 1.  The utility of EEG, SSEP, and other neurophysiologic tools to guide neurocritical care.

Authors:  Eric S Rosenthal
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Hyperammonemia associated with distal renal tubular acidosis or urinary tract infection: a systematic review.

Authors:  Caterina M Clericetti; Gregorio P Milani; Sebastiano A G Lava; Mario G Bianchetti; Giacomo D Simonetti; Olivier Giannini
Journal:  Pediatr Nephrol       Date:  2017-11-13       Impact factor: 3.714

Review 3.  Valproate-induced hyperammonaemia superimposed upon severe neuropsychiatric lupus: a case report and review of the literature.

Authors:  Estee Chan; Fiona McQueen
Journal:  Clin Rheumatol       Date:  2012-12-28       Impact factor: 2.980

Review 4.  Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

5.  Hyperammonemic encephalopathy caused by carnitine deficiency.

Authors:  Berkeley N Limketkai; Stephen D Zucker
Journal:  J Gen Intern Med       Date:  2007-12-13       Impact factor: 5.128

6.  Hyperammonemia-induced encephalopathy: A rare devastating complication of bariatric surgery.

Authors:  Michelle L Kromas; Omar Y Mousa; Savio John
Journal:  World J Hepatol       Date:  2015-05-08

7.  Clinical Relevance and Cost-Savings of Levocarnitine Versus Ammonul in the Management Of Hyperammonemia in a Cancer Patient: The Impact of a Clinical Pharmacist.

Authors:  Chukwuma Anyanwu; Chinonso Ezeudu; Hoa Le; Oliver Egwim
Journal:  P T       Date:  2018-01

8.  Valproate-induced hyperammonemic encephalopathy enhanced by topiramate and phenobarbitone: a case report and an update.

Authors:  S Vivekanandan; S Dinesh Nayak
Journal:  Ann Indian Acad Neurol       Date:  2010-04       Impact factor: 1.383

Review 9.  Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?

Authors:  Philippe E R Lheureux; Andrea Penaloza; Soheil Zahir; Mireille Gris
Journal:  Crit Care       Date:  2005-06-10       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.